Pivotal NOAC trial may have been compromised: BMJ

By Anna Evangeli and Rada Rouse

Update, 8 February: The European Medicines Agency (EMA) has concluded after an investigation that a defect with the INR device used in the ROCKET AF trial does not change its assessment of the overall safety or benefit-risk balance of rivaroxaban. 

Any incorrect measurements obtained wih the defective device would have had "only a marginal effect" on the study results, the EMA said in a statement.

*      *      *

RESULTS from a

Latest